Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 20/20 | 0.77 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6093448 | 1.00 | CCR5 (0.77) | CCR5KCNH2CYP2D6 | |
| SCHEMBL6091798 | 0.91 | CCR5 (0.72) | CCR5 | |
| SCHEMBL6091792 | 0.91 | CCR5 (0.72) | CCR5 | |
| SCHEMBL6645202 | 0.89 | CCR5 (0.72) | CCR5KCNH2CYP2D6 | |
| SCHEMBL6645199 | 0.89 | CCR5 (0.72) | CCR5KCNH2CYP2D6 | |
| SCHEMBL6645133 | 0.88 | CCR5 (0.72) | CCR5KCNH2CYP2D6 | |
| SCHEMBL6645138 | 0.88 | CCR5 (0.72) | CCR5KCNH2CYP2D6 | |
| SCHEMBL6649822 | 0.88 | CCR5 (0.74) | CCR5KCNH2CYP2D6 | |
| SCHEMBL6649818 | 0.88 | CCR5 (0.74) | CCR5KCNH2CYP2D6 | |
| SCHEMBL6648581 | 0.87 | CCR5 (0.76) | CCR5KCNH2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060167048-A1 | N-4-piperidinyl compounds as ccr5 modulators | ASTRAZENECA AB (SE) | 2006-07-27 | — | — | US | disclosed |
| US-20050171353-A1 | Piperidine or 8-aza-bicyclo[3.2.1]oct-3-yl derivatives useful as modulators of chemokine receptor activity (especially ccr5) | ASTRAZENECA AB (SE) | 2005-08-04 | — | — | US | disclosed |
| US-20040266823-A1 | Novel piperidine derivatives as modulators of chemokine receptors | ASTRAZENECA AB (SE) | 2004-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171353-A1 | Piperidine or 8-aza-bicyclo[3.2.1]oct-3-yl derivatives useful as modulators of chemokine receptor activity (especially ccr5) | CCR5, CXCR1, CCR7 | CCR5 1/4885KCNH2 1730/4885CYP2D6 1950/4885 |
| US-20060167048-A1 | N-4-piperidinyl compounds as ccr5 modulators | CCR5, CCL5, CCR2 | CCR5 1/4885KCNH2 2731/4885CYP2D6 1189/4885 |
| US-20040266823-A1 | Novel piperidine derivatives as modulators of chemokine receptors | CCR5, CCR2, CX3CR1 | CCR5 1/4885KCNH2 2886/4885CYP2D6 2335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.